Related Experiment Video
Updated: Jan 12, 2026

Three Dimensional Cultures: A Tool To Study Normal Acinar Architecture vs. Malignant Transformation Of Breast Cells
Published on: April 25, 2014
Targeting the N-cadherin/β-catenin axis with MSAB reverses malignant phenotypes in blast crisis of CML
Yingying Zhou1, Songqin Jian2, Lijun Lu1
1Department of Laboratory Medicine, Huangyan Hospital of Wenzhou Medical University, Taizhou First People's Hospital, Taizhou, Zhejiang, China.
Introduction:
The molecular mechanisms underlying chronic myeloid leukemia (CML) progression from chronic phase (CP) to blast crisis (BC) remain incompletely understood. This study aimed to identify progression-specific genes and elucidate the role of N-cadherin (CDH2) in BC transformation.
Methods:
We analyzed the GSE4170 dataset to identify differentially expressed genes (DEGs) across CML phases. Functional annotations were performed via GSEA, GO, and KEGG analyses. The role of N-cadherin was validated using in vitro (KU812 cell line) and in vivo (nude mouse xenograft) models. The β-catenin inhibitor MSAB was employed for mechanistic studies.
Results:
Transcriptomic analysis identified 1,294 DEGs during CML progression, with 41 "progression-specific" genes showing consistent expression trends. Among these, N-cadherin was significantly upregulated in BC patient samples. Overexpression of N-cadherin in KU812 cells promoted cell cycle entry, accelerated tumor growth in vivo, and suppressed the expression of granulocyte surface differentiation antigens. MSAB treatment effectively reversed these malignant phenotypes. Furthermore, CDH2 mRNA was notably upregulated in advanced-phase samples compared to chronic-phase samples.
Discussion:
Our findings elucidate the role of CDH2 in CML progression through activation of the Wnt/β-catenin signaling pathway. Targeting the N-cadherin/β-catenin axis with MSAB may represent a novel therapeutic strategy for BC-CML.
Insights
N-cadherin (CDH2) drives chronic myeloid leukemia (CML) progression to blast crisis by activating Wnt/β-catenin signaling. Inhibiting this pathway with MSAB offers a potential therapeutic strategy for advanced CML.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Chronic myeloid leukemia (CML) progression from chronic phase (CP) to blast crisis (BC) involves complex molecular mechanisms.
- Understanding these mechanisms is crucial for developing effective treatments for advanced CML.
Purpose of the Study:
- Identify genes driving CML progression from CP to BC.
- Elucidate the specific role of N-cadherin (CDH2) in BC transformation.
Main Methods:
- Analyzed the GSE4170 dataset for differentially expressed genes (DEGs) in CML phases.
- Utilized Gene Set Enrichment Analysis (GSEA), Gene Ontology (GO), and KEGG pathway analyses for functional annotation.
- Validated N-cadherin's role using in vitro (KU812 cells) and in vivo (nude mouse xenograft) models.
- Investigated mechanisms using the β-catenin inhibitor MSAB.
Main Results:
- Identified 1,294 DEGs, with 41 progression-specific genes.
- Found significant upregulation of N-cadherin (CDH2) in BC samples.
- N-cadherin overexpression promoted cell cycle entry, accelerated tumor growth, and suppressed differentiation.
- MSAB treatment reversed these malignant phenotypes, indicating CDH2's role via Wnt/β-catenin signaling.
Conclusions:
- CDH2 plays a critical role in CML progression to BC by activating the Wnt/β-catenin pathway.
- Targeting the N-cadherin/β-catenin axis with MSAB presents a promising therapeutic strategy for BC-CML.
Related Concept Videos
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

